drugset / Trial / NCT05333419
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single dose (100 ng/day) study to assess the safety, tolerability and biodegradation of the PA5436 Latanoprost FA SR Ocular Implant in adults who have OAG or OHT.
Timeline
- Start
- 2022-03-04
- Primary completion
- 2023-06-12
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | latanoprost free acid | Unknown | 100 ng | Other |